Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hep B Cure May Lie In Reducing Surface Antigen

Executive Summary

Among the topics at the European liver meeting was whether reducing HBV surface antigen might be part of a combination approach to curing chronic hepatitis B. One of the leaders in this approach, Arbutus, is working toward its own internal combo therapy for the virus.

Advertisement

Related Content

J&J’s Comprehensive Approach To Finding A ‘Functional Cure’ For HBV
Arrowhead Tumbles As FDA Puts A Clinical Hold On Novel HBV Therapy Trial
ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy
Tekmira suspends Ebola work; changes name, focus
New HBV Technologies Start To Take Hold In Quest For A Cure

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098647

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel